Product Center
Yisuda®Suraxavir Marboxil Tablets
Yisuda®Suraxavir Marboxil Tablets are a novel antiviral medication for the treatment of uncomplicated influenza A and B in previously healthy adolescents aged 12 and above, and adults.
Aurantii® Fructus Immaturus Total Flavonoids Tablet
Aurantii® Fructus Immaturus Total Flavonoids Tablet have good therapeutic effects on common symptoms of functional dyspepsia (such as liver-stomach disharmony, spleen-stomach damp-heat, food stagnation, and spleen-stomach deficiency).
Xiyanping Injection
Xiyanping Injection is a traditional Chinese medicine injection made from total sulfated andrographolide, a key component of Andrographis paniculata. It is part of the National “12th Five-Year Plan” Major Innovative Drug Discovery Project.
Qingruitan®Brivaracetam Tablets
Brivaracetam is an innovative third-generation antiepileptic drug that selectively targets synaptic vesicle protein 2A (SV2A) with high affinity.
Bangkaxin®Esomeprazole Magnesium Enteric-coated Tablets
Bangkaxin® Esomeprazole Magnesium Enteric-coated Tablets are a new generation of proton pump inhibitors (PPIs), approved as a Class 4 chemical drug. It is the only esomeprazole magnesium enteric-coated tablet in China that is bioequivalent to the original brand. It is clinically used for the prevention and treatment of acid-related diseases such as gastroesophageal reflux disease (GERD), peptic ulcers, stress ulcers, Helicobacter pylori eradication, and drug-induced gastric mucosal injury. It is widely used in clinical practice and is a first-line choice for acid suppression therapy and ulcer prevention and treatment.
Kepalb®Palbociclib Capsuless
Kepalb® Palbociclib Capsuless are an oral CDK4/6 inhibitor that selectively targets and inhibits the activity of the CDK4/6-Cyclin D1 complex. This prevents tumor cells from passing through the G1 to S phase checkpoint, blocking the cell cycle and inhibiting tumor cell proliferation.It is primarily used for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer, in combination with aromatase inhibitors as initial endocrine therapy for postmenopausal women.
Langkang® Perampanel Tablets
Langkang® Perampanel Tablets are a third-generation antiepileptic drug (ASM) that non-competitively binds to the AMPA glutamate receptor on postsynaptic neurons.
Xinkun® Sodium Valproate Concentrated Solution for Injection
Xinkun® Sodium Valproate Concentrated Solution for Injection is a classic broad-spectrum anti-epileptic drug.
Qingruike® Pregabalin Oral Solution
Qingruike® Pregabalin Oral Solution contains pregabalin, a calcium channel modulator that targets the α2-δ subunit of voltage-gated calcium channels. Besides relieving pain, it also improves sleep and mood.
Kerilin®Eribulin Mesylate Injection
Kerilin®Eribulin Mesylate Injection was approved by NMPA on January 14, 2025. It is the second drug for breast cancer launched by Qingfeng Pharmaceutical Group following Palbociclib Capsules. Having passed the generic drug consistency evaluation, it is therapeutically equivalent to the originator product with a more favorable price, providing breast cancer patients with more treatment options.
Zenza® Enzalutamide Soft Capsules
Enzalutamide Soft Capsules are a medication for patients with advanced prostate cancer. It is primarily indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of metastasis, and for adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) and have not received chemotherapy.
Keraf®Sorafenib Tosylate Tablets
Keraf®Sorafenib Tosylate Tablets are a multi-target oral medication for treating tumors, with dual mechanisms of action. It inhibits tumor angiogenesis by blocking VEGFR and PDGFR and suppresses tumor cell proliferation by blocking the Raf/MEK/ERK signaling pathway, indirectly inhibiting tumor cell growth. It was approved for market in August 2020. It is primarily used for the treatment of renal cancer, liver cancer, and thyroid cancer.
Kegora®Regorafenib Tablets
Regorafenib is an oral multi-kinase inhibitor that targets multiple tumor signaling pathways. With a broad spectrum of targets, it inhibits both the VEGF pathway and its bypass mechanisms, effectively disrupting inter-pathway crosstalk.
Yisuda®Suraxavir Marboxil Tablets
Yisuda®Suraxavir Marboxil Tablets are a novel antiviral medication for the treatment of uncomplicated influenza A and B in previously healthy adolescents aged 12 and above, and adults.
